# ZAP, US. Zomig for Appropriate for Primary Care

> **NCT00637286** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 120 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Zolmitriptan

## Key facts

- **NCT ID:** NCT00637286
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2009-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637286, "ZAP, US. Zomig for Appropriate for Primary Care". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00637286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*